What does Quizatinib do?

Quizartinib (Quizartinib, trade name Vanflyta, is an innovative small molecule oral receptor tyrosine kinase inhibitor specifically used to treat FLT3-ITD mutation-positive acute myeloid leukemia (AML). This drug shows potential in the treatment of AML by targeting the FLT3 receptor.

FLT3 mutation is a common genetic abnormality in AML, among which FLT3-ITD mutation is particularly common and closely related to disease recurrence and poor prognosis. The mechanism of action of quizartinib is that it can specifically inhibit FLT3 kinase activity, thereby blocking the autophosphorylation process of the FLT3 receptor, thereby inhibiting downstream signaling pathways and effectively inhibiting FLT3-ITD mutation-dependent leukemia cell proliferation.

In clinical application, quizartinib has shown good therapeutic effects. For patients with newly diagnosed FLT3-ITD-positive AML, quizartinib, used in combination with standard cytarabine and anthracyclines as part of induction and consolidation therapy, can significantly extend progression-free survival (PFS) and overall survival (OS). Quizartinib also shows certain efficacy for patients with relapsed or refractory FLT3-ITD-positive AML, providing patients with a new treatment option.

In addition, quizartinib is relatively well tolerated. Although some adverse reactions may occur during treatment, such as nausea, vomiting, diarrhea, fatigue, etc., most patients can be effectively managed through dose adjustment or symptomatic treatment. However, it is important to note that quizartinib is contraindicated in patients with severe hypokalemia, severe hypomagnesemia, long QT syndrome, or a history of ventricular arrhythmias or torsade de pointes, as these conditions may increase the risk of cardiotoxicity.

In general, quizartinib, as a therapeutic drug targeting FLT3-ITD mutation-positive AML, brings new treatment hope to AML patients by precisely inhibiting FLT3 kinase activity. However, when using quizartinib, doctors need to carefully evaluate the patient's condition and physical condition to ensure the safety and effectiveness of the medication.

xa0

Reference materials:https://www.drugs.com/vanflyta.html